. 2016 Mar 31;7(20):29011–29022. doi: 10.18632/oncotarget.8508

Table 1. IC₅₀ values for inhibition of ALK Y1604 phosphorylation by brigatinib or crizotinib in PC12 cells.

ALK mutations	IC50 (nM)		Fold difference
ALK mutations	brigatinib	crizotinib	Fold difference
WT	2.6± 0.2	19.68 ± 9	8
G1128A	2.0 ± 0.6	41.82 ± 5	21
I1171N	10.2 ± 5.7	110.90 ± 18	11
F1174L	1.5 ± 0.4	25.35 ± 10	17
R1192P	2.5 ± 0.4	64.0 ± 12	26
F1245C	6.6 ± 0.3	34.07 ± 0	5
G1269A	3.4 ± 2.0	118.9 ± 23	35
R1275Q	4.2 ± 0.7	32.58 ± 0	8
Y1278S	4.6 ± 0.2	72.44 ± 2	16

IC₅₀ values were determined by quantification of Y1604 phosphorylation from the immunoblots in Figure 2A and 2B. Values represent mean ± SD from at least two independent experiments.

Table 1. IC50 values for inhibition of ALK Y1604 phosphorylation by brigatinib or crizotinib in PC12 cells.

Table 1. IC₅₀ values for inhibition of ALK Y1604 phosphorylation by brigatinib or crizotinib in PC12 cells.